IL-36家族失调驱动银屑病关节炎关节炎症与治疗反应
该研究对早期未治疗银屑病关节炎(PsA)和类风湿关节炎(RA)患者滑膜组织进行RNA测序和免疫组化,发现PsA滑膜中IL-36拮抗剂表达降低而激动剂与RA相当,且中性粒细胞相关分子上调;基线IL-36α高表达与DMARDs无应答相关,体外PsA成纤维细胞对IL-36刺激更敏感且DMARDs增加IL-36表达。
要点
- PsA滑膜中IL-36拮抗剂表达降低,激动剂与RA相当,提示IL-36轴失衡。
- 基线滑膜IL-36α高表达与PsA患者DMARDs无应答相关,且6个月后仍持续。
- 体外PsA成纤维细胞对IL-36刺激更敏感,DMARDs增加其IL-36表达。
核心结论
- PsA滑膜中IL-36激动剂-拮抗剂平衡受损及对DMARDs敏感性降低可能解释DMARDs在PsA中疗效低于RA。
- 外源性补充IL-36拮抗剂可能是PsA有前景的新治疗靶点。
研究设计与样本
- 研究纳入早期未治疗PsA和RA患者,基线及DMARDs治疗6个月后经超声引导滑膜活检采集组织。
- 采用RNA测序和免疫组化检测IL-36家族成员,并与离体DMARDs治疗反应进行相关性分析。
- 体外实验使用原代PsA和RA成纤维样滑膜细胞研究DMARDs对IL-36的影响。
主要发现
- PsA滑膜中IL-36拮抗剂表达降低,而IL-36激动剂在PsA与RA之间相当。
- 与RA相比,PsA中驱动IL-36通路更高活化的中性粒细胞相关分子上调。
- 基线时PsA对DMARDs无应答者的滑膜IL-36α表达显著更高,且该差异表达在治疗后6个月持续存在。
- 体外原代PsA来源成纤维细胞对IL-36刺激的反应性高于RA,且DMARDs处理增加PsA成纤维细胞中IL-36表达。
临床怎么用
- 基线滑膜IL-36α高表达可能提示PsA患者对DMARDs应答不佳。
- 外源性补充IL-36拮抗剂可能成为PsA的潜在治疗策略。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: IL-36 agonists are pro-inflammatory cytokines involved in the pathogenesis of psoriasis. However, their role in the pathogenesis of arthritis and treatment response to DMARDs in PsA remains uncertain. Therefore, we investigated the IL-36 axis in the synovium of early, treatment-naïve PsA, and for comparison RA patients, pre- and post-DMARDs therapy. METHODS: Synovial tissues were collected by US-guided biopsy from patients with early, treatment-naïve PsA and RA at baseline and 6 months after DMARDs therapy. IL-36 family members were investigated in synovium by RNA sequencing and immunohistochemistry, and expression levels correlated with DMARDs treatment response ex vivo. Additionally, DMARDs effects on IL-36 were investigated in vitro in fibroblast-like synoviocytes. RESULTS: PsA synovium displayed a reduced expression of IL-36 antagonists, while IL-36 agonists were comparable between PsA and RA. Additionally, neutrophil-related molecules, which drive a higher activation of the IL-36 pathway, were upregulated in PsA compared with RA. At baseline, the synovial expression of IL-36α was significantly higher in PsA non-responders to DMARDs treatment, with the differential expression being sustained at 6 months post-treatment. In vitro, primary PsA-derived fibroblasts were more responsive to IL-36 stimulation compared with RA and, importantly, DMARDs treatment increased IL-36 expression in PsA fibroblasts. CONCLUSION: The impaired balance between IL-36 agonists-antagonists described herein for the first time in PsA synovium and the decreased sensitivity to DMARDs in vitro may explain the apparent lower efficacy of DMARDs in PsA compared with RA. Exogenous replacement of IL-36 antagonists may be a novel promising therapeutic target for PsA patients.
引用
- Boutet MA, Nerviani A, Lliso-Ribera G, et al. Interleukin-36 family dysregulation drives joint inflammation and therapy response in psoriatic arthritis. Rheumatology (Oxford). 2020. PMID: 31504934. doi:10.1093/rheumatology/kez358
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。